pralatraxate,

Phase 1Small molecule

NNew York Medical College

pralatraxate, is one of 10 small molecule programs targeting NK-Cell Lymphoma. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

NK-Cell LymphomaRecruiting

NK-Cell LymphomaPhase 1

Recruiting

Competition

Competitive Landscape

9 competitors in NK-Cell Lymphoma

#DrugCompanyPhaseTrials

Trexall

Jazz Pharmaceuticals

Phase 1

1 2

Adriamycin

Pfizer

Phase 1

1 3

Adcetris

Pfizer

Phase 1

1 4

Ifex

BBaxter Healthcare Corporation

Phase 1

1 5

Decadron

AAspen Global Incorporated

Phase 1

1 6

Vepesid

AAvyxa

Phase 1

1 7

ASPARLAS

SServier

Phase 1

1 8

Cytoxan

BBaxter Healthcare Corporation

Phase 1

1 9

Rayos

RRoxane Laboratories

Phase 1

1 10

pralatraxate,

NNew York Medical College

Phase 1

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2028

Phase 1Recruiting

NK-Cell Lymphoma

NCT03719105

Clinical

Trials by Indication[1]

NK-Cell Lymphoma1 trial

Pilot Study Using Induction Chemo-immunotherapy Followed by Consolidation With Reduced Toxicity Conditioning and Allogenic Stem Cell Transplant in Advanced Stage Mature Non-anaplastic T-Cell or NK Lymphoma/Leukemia in Children, Adolescents and Young Adults; A NK/T-Cell Lymphoma/Leukemia Consortium Study

Recruiting·NNew York Medical College·Phase 1·NCT03719105·40 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for pralatraxate,. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — pralatraxate, compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for pralatraxate,. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — New York Medical College company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: NNew York Medical College

pralatraxate,

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2028

Trials by Indication[1]

NK-Cell Lymphoma1 trial

References

Drug Info

Quick Facts

Related News